Share on LinkedInShare on LinkedIn

ARTICLE · 26 APRIL 2002

Repackaging Pharmaceuticals - Scant Guidance From the ECJ

United KingdomIntellectual Property
Lucy Harrold
Lucy Harrold
The long awaited ECJ Decisions in Merck, Sharp & Dohme GmbH v. Paranova Pharmazeutika Handels GmbH and Boehringer Ingelheim (and others) v. Swingward Limited (and another) provide scant guidance on the circumstances in which a pharmaceutical company may object to the repackaging of its branded goods

Background

The cases of Merck v.Paranova (referred by the Oberlandesgericht Wien) and Boehringer v. Swingward (referred by the High Court in London) consider the question of when a trade mark proprietor is entitled to rely on its trade mark rights to prevent repackaging of its goods by parallel importers. Both cases involve parallel importation of branded pharmaceutical products within the EEA that have been repackaged and the trade marks reaffixed to the outer packaging. The Advocate General gave his Opinion on the two cases in July of last year and that has largely been followed

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from